News Sentiment

IMA sentiment intelligence

ImageneBio, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 20 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.38 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

79/100 classification confidence.

Company focus 11

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-9.0% over one week, -10.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

ImageneBio, Inc. Financial Disclosures & SEC Filings

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 79/100 classification
One-week reaction -9.0% Price reacting lower
Trend fit Trend inactive -10.3% over four weeks
Fair value -70.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 5
Neutral 13
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 11
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 6
TradingView 4
Stock Titan 3
simplywall.st 2
AD HOC NEWS 2
MarketBeat 1
Quiver Quantitative 1
The Globe and Mail 1

Event Lens

What the news is about

Classified themes
Earnings 12
Market update 7
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-20 of 20
MarketBeat Direct company coverage

ImageneBio (NASDAQ:IMA) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen has downgraded ImageneBio (NASDAQ:IMA) from a "hold" to a "sell" rating due to a more bearish outlook on the biotech stock. This decision follows the company's recent quarterly earnings report, where it posted a wider-than-expected loss of -$0.95 EPS, significantl

Tone
Negative 19/100
Event
Earnings
Published
11 May 2026 06:10
Source
MarketBeat
Stock Titan Direct company coverage

ImageneBio (NASDAQ: IMA) plans 2026 virtual meeting and equity plan vote

ImageneBio (NASDAQ: IMA) has announced its 2026 virtual Annual Meeting of Stockholders for June 16, 2026. Shareholders will vote on the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026, and the approval of an a

Tone
Neutral 50/100
Event
Regulatory and legal
Published
30 Apr 2026 21:10
Source
Stock Titan
AD HOC NEWS Direct company coverage

Ikena Oncology Inc Stock: Navigating Biotechnology Innovation Amid Recent Reverse Split and Symbol C

Ikena Oncology Inc (ISIN: US4517401090), a clinical-stage precision oncology company, recently executed a 1-for-12 reverse stock split and symbol change to IMA, reshaping its market position for North American investors focused on targeted cancer therapies. The company is develop

Tone
Positive 61/100
Event
Market update
Published
01 Apr 2026 14:33
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Ikena Oncology Inc Stock: Navigating Biotechnology Innovation Amid Recent Reverse Split and Symbol Change

Ikena Oncology Inc recently underwent a 1-for-12 reverse stock split and symbol change to IMA, aiming to enhance its market position for North American investors. The clinical-stage precision oncology company, which specializes in small molecule therapeutics for hard-to-treat can

Tone
Positive 76/100
Event
Market update
Published
01 Apr 2026 12:10
Source
AD HOC NEWS
Stock Titan Direct company coverage

ImageneBio (NASDAQ: IMA) names Bob Lally Principal Accounting Officer as Erin Butler departs

ImageneBio, Inc. announced a mutual separation with its Senior Vice President, Finance & Administration and Principal Accounting Officer, Erin Butler, effective March 20, 2026. Bob Lally, currently Senior Vice President, Finance & Operations, has been appointed as her successor f

Tone
Neutral 50/100
Event
Market update
Published
17 Mar 2026 20:09
Source
Stock Titan
The Globe and Mail Direct company coverage

ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

ImageneBio, Inc. reported its financial results for Q4 and full year 2025, highlighting the ongoing Phase 2b ADAPTIVE trial for IMG-007 in atopic dermatitis with promising early safety data and a topline readout expected in 2027. The company also announced key executive hires and

Tone
Positive 74/100
Event
Earnings
Published
12 Mar 2026 15:40
Source
The Globe and Mail
Stock Titan Direct company coverage

[Form 4] Ikena Oncology, Inc. Insider Trading Activity

This article details an insider trading Form 4 filing for Ikena Oncology, Inc. (now ImageneBio, Inc.) by director Stampacchia Otello. The filing indicates a net purchase of 267,556 shares valued at approximately $8 million on July 25, 2025, primarily through Omega Fund VI, L.P. T

Tone
Positive 72/100
Event
Market update
Published
30 Jul 2025 04:47
Source
Stock Titan